课题基金 / 基金详情

Heme and heme degradation products as effectors of hepatic perfusion and excretion failure

Heme and heme degradation products as effectors of hepatic perfusion and excretion failure
血红素和血红素降解产物作为肝灌注和排泄失败的效应物
批准号:
214875369
负责人:
Professor Dr. Michael Bauer
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Units
财政年份:
2012
资助国家:
德国
项目状态:
已结题
起止时间:
2011-12-31 至 2019-12-31

项目摘要

项目成果

Professor Dr. Michael Bauer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Extracellular "free" heme is increasingly recognized to promote the development of sepsisassociated organ failure. Vice versa, buffering or degradation of tissue free heme has been shown to mediate "disease tolerance", a state in which presence of bacteria does not propagate organ dysfunction. The development of strategies to induce disease tolerance is necessary because conventional strategies to control progression from uncomplicated infection to sepsis with organ failure are limited in the light of an increasing burden of antimicrobial resistances.The prognostic significance of development of hepatic excretory failure in bacterial sepsis was previously demonstrated by our group. In the first funding period of FOR 1738, we confirmed an unexpected role of heme as a strong vasoconstrictor and cytotoxic factor which could beneutralized by albumin. Similarly, profound protection against hemodynamic and cytotoxic actions of heme could be achieved by prior induction of heme oxygenase gene expression. Bilirubin oxidation end products Z-BOX A and B as higher-order metabolites of heme degradation failed to affect vascular tone but could be characterized as partial agonists of Rev-erba, a transcriptional regulator of tissue development and circadian rhythm. Both BOXes acted on the organization of the hepatocellular cytoskeleton, an important factor controlling the canalicular membrane organization associated with hepatic excretory failure.In this funding period we aim to further characterize the role of heme and heme degradation products (HHDPs) in the pathogenesis of sepsis-induced excretory liver failure. Specifically, we will characterize the cell type-specific adaptive role of heme oxygenase 1 (HO1) by tamoxifeninduced unspecific or cell type-specific knock-down of its gene expression in hepatocytes, Kupffer cells and vascular endothelium, and, thus, investigating the role of HHDPs in distinct compartments. Conditional and cell type-specific knock-down mouse strains will be subjected to both, assessment of hemodynamic response to heme perfusion as well as to systematic studies of their stress tolerance in health and disease with or without prior induction of HO1. These model systems will enable us to study the interaction of heme as a constrictor and carbon monoxide (CO) as a dilator generated upon heme degradation and factors that limit HO1-mediated protection, such as formation of BOXes A and B. These higher-order metabolites of bilirubin will be tested specifically regarding their role in disturbing the canalicular membrane organization upon inflammatory stimuli. These studies will characterize the unexpected functions of heme as well as its degradation products Z-BOX A and B on hepatic cell morphology and function observed in the first funding period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Time-resolved low energy photoelectron diffraction for the study of surface structural dynamics with sub-100 fs temporal resolution
Time-resolved studies of ultrafast electronic processes in two-dimensional solids in the strongly non-thermal regime
Jena Biophotonic and Imaging Laboratory
Ultrakurzeitdynamik von Ordnungsprozessen in stark korrelierten Festkörpern untersucht mit zeit- und winkelaufgelöster XUV-Photoelektronenspektroskopie
国内基金
海外基金
高等植物细胞色素b6f复合体血红素辅基Heme cn组装的分子机理研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    彭连伟
  • 依托单位:
青蒿素类药物被heme激活后的代谢过程以及耐药疟原虫的代谢防御机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    邢杰
  • 依托单位:
不依赖heme的脱羧酶undA的理性设计改造
肉品中肌红蛋白Heme/Hemin辅基介导的肌球蛋白与水分子互作机制
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
  • 依托单位: